Condition: Alzheimer's Disease · Dementia · Sponsor: FORUM Pharmaceuticals Inc
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Study site | Phoenix, Arizona, United States | — |
| Study site | Tucson, Arizona, United States | — |
| Study site | Little Rock, Arkansas, United States | — |
| Study site | Costa Mesa, California, United States | — |
| Study site | Culver City, California, United States | — |
| Study site | Encino, California, United States | — |
| Study site | Glendale, California, United States | — |
| Study site | Long Beach, California, United States | — |
| Study site | Los Alamitos, California, United States | — |
| Study site | Orange, California, United States | — |
| Study site | Redding, California, United States | — |
| Study site | San Diego, California, United States | — |
+ 74 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02004392